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OBJECTIVES We tested whether in vivo nitroglycerin (NTG) treatment causes tyrosine nitration of
prostacyclin synthase (PGI2-S), one of the nitration targets of peroxynitrite, and whether this
may contribute to nitrate tolerance.
BACKGROUND Long-term NTG therapy causes tolerance secondary to increased vasoconstrictor sensitivity
and increased vascular formation of reactive oxygen species. Because NTG releases nitric
oxide (NO), NTG-induced stimulation of superoxide production should increase vascular
nitrotyrosine levels, compatible with increased formation of peroxynitrite, the reaction
product from NO and superoxide.
METHODS New Zealand White rabbits and Wistar rats were treated with NTG (0.4 mg/h for 3 days).
Tolerance was assessed with isometric tension studies. Vascular peroxynitrite levels were
quantified with luminol-derived chemiluminescence (LDCL) and peroxynitrite scavengers,
such as uric acid and ebselen. As a surrogate parameter for the assessment of the activity of
cyclic guanosine monophosphate-dependent kinase-I (cGK-I; the final signaling pathway for
NO), the phosphorylation of the vasodilator-stimulated phosphoprotein (P-VASP) at serine
239 was analyzed.
RESULTS Nitroglycerin treatment increased LDCL, and the inhibitory effect of uric acid and ebselen on
LDCL was augmented in tolerant rings. Immunoprecipitation of 3-nitrotyrosine–containing
proteins and immunohistochemistry analysis identified PGI2-S as a tyrosine-nitrated protein.
Accordingly, conversion of (14C)-PGH2 into 6-keto-PGF1 (PGI2-S activity) was strongly
inhibited. In vitro incubation of tolerant rings with ebselen and uric acid markedly increased
the depressed P-VASP levels and improved NTG sensitivity of the tolerant vasculature.
CONCLUSIONS Nitroglycerin-induced vascular peroxynitrite formation inhibits the activity of PGI2-S as well
as NO, cGMP, and cGK-I signaling, which may contribute to vascular dysfunction in the
setting of tolerance. (J Am Coll Cardiol 2003;42:1826–34) © 2003 by the American
College of Cardiology Foundation
Nitrates are still widely used in the management of coronary
artery disease, including patients with stable and unstable
angina, acute myocardial infarction, and congestive heart
failure (1). The therapeutic efficacy of these nitrates is due to
peripheral venous and arterial dilation that results in de-
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creased myocardial oxygen consumption. Nitrates also dilate
large coronary arteries and collateral channels (1), while
having minimal or no effect on arteriolar tone (2). It is
assumed that nitroglycerin (NTG) induces vasorelaxation
by releasing the vasoactive principle nitric oxide (NO) via an
enzymatic biotransformation step. This may include gluta-
thione S transferases (3), the cytochrome p450 system (4),
xanthine oxidoreductases (5), or the mitochondrial aldehyde
dehydrogenase (6). The NTG metabolite NO activates the
target enzyme soluble guanylyl cyclase (sGC) and increases
tissue levels of the second messenger cyclic guanosine
monophosphate (cGMP). Cyclic guanosine monophos-
phate, in turn, activates a cGMP-dependent protein kinase
(cGK-I), which has been shown to mediate vasorelaxation
via phosphorylation of proteins that regulate intracellular
Ca2 levels (7).
Two major drawbacks of nitrate therapy have been
identified as important: the rapid development of tolerance
within 24 to 48 h of continuous NTG treatment (8,9) and
the development of endothelial dysfunction during pro-
longed NTG treatment (so called cross-tolerance) (10–12).
Recently, we and others have shown that NTG therapy
increases vascular superoxide, which reduces the bioavail-
ability of NO and thus may interfere with activation of sGC
(13) and cGK-I (13,14). Because NTG releases NO in the
vascular wall, NTG-induced superoxide production should
ultimately lead to increased formation of the NO/
superoxide reaction product peroxynitrite. Indeed, several
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groups have shown that in vitro or in vivo exposure to NTG
leads to increased urinary (15) and vascular nitrotyrosine
content (16,17), compatible with increased peroxynitrite
formation. This peroxide is unstable and rapidly decom-
poses to nitrite and nitrate with a half-life of 1 s (18).
Recent studies have also shown that peroxynitrite preferen-
tially inactivates prostacyclin synthase (PGI2-S) by a mech-
anism dependent on tyrosine nitration (19,20). Inactivation
of PGI2-S by peroxynitrite could have confounding effects
on NTG vasodilator potency because several groups have
shown that NTG and/or the active metabolite NO has
potent stimulatory effects on PGI2-S and that a considerable
part of NTG-induced vasodilation is due to the release of
PGI2 (21,22).
The aim of the present study was therefore to test
whether NTG treatment results in increased vascular per-
oxynitrite formation and whether this may lead to nitration
and inhibition of PGI2-S and inhibition of cGK-I activity
as a cause of nitrate tolerance.
METHODS
Animal model: in vivo nitrate tolerance. New Zealand
White rabbits and Wistar rats were studied. Tolerance was
induced with NTG patches (10) or ALZET (Cupertino,
California) osmotic minipumps, as described recently (23).
Luminol-derived chemiluminescence (LDCL). Peroxy-
nitrite production in intact vessels was measured with
LDCL (100 mol/l) as described (24). Because luminol
detects superoxide as well as hydrogen peroxide and per-
oxynitrite, we used peroxynitrite trapping agents such as uric
acid and ebselen to quantify vascular peroxynitrite forma-
tion, as described (24).
Detection of cGK-I expression, cGK-I activity, and
phosphorylation of vasodilator-stimulated phosphopro-
tein (P-VASP) at serine 239. Aortic tissue was frozen and
homogenized in liquid nitrogen. Sodium dodecyl sulfate–
polyacrylamide gel electrophoresis (SDS-PAGE) and elec-
troblotting were performed as described (25). All data
reported here indicate P-VASP at serine 239.
In separate experiments, the aortas from control and
NTG-treated rabbits were incubated with ebselen and
uric acid (10 mol/l), scavengers for peroxynitrite or
peroxynitrite-derived radicals, to test whether the cGMP
signaling pathway downstream of sGC is impaired by
increased vascular peroxynitrite levels.
Organ chamber experiments. Vasodilator responses to
NTG were assessed in organ chambers, as described re-
cently (10). To determine the effects of PGI2-S on vascular
sensitivity to NTG, vessels were incubated for 30 min with
the PGI2-S/thromboxane A2 (TXA2) inhibitor U51605
(100 mol/l) (26). These experiments were performed in
the absence of indomethacin.
Immunoprecipitation and Western blots. Immunopre-
cipitation of nitrotyrosine-containing proteins was done as
described recently (19). For Western blots, protein precip-
itates were separated by 7.5% SDS-PAGE and blotted onto
a nitrocellulose membrane (19). After blocking, the mem-
branes were incubated with a polyclonal antibody directed
against PGI2-S, following immunostaining and documen-
tation of positive bands by enhanced chemiluminescence.
Immunohistochemistry. Aortic tissue from Wistar rats
(sham or NTG-treated) was fixed in 4% formalin buffer for
1 h at 4°C. Then, the sucrose concentration was increased in
three steps up to 30% (wt/vol) with 0.05% (wt/vol) of
cacodylic acid. The tissue was then embedded in tissue tek
(Sakura Finetek/Science Services, Munich, Germany), and
cryosections of 10 m were prepared and mounted on
poly-L-lysine–coated slides. After air drying, the slides were
blocked with 10% bovine serum albumin (wt/vol) and 3%
(vol/vol) Triton-X100 in phosphate-buffered saline (PBS)
for 1 h at room temperature. The slides were incubated with
either the primary antibodies against PGI2-S (dilution
1:100; gift of Dr. T. Klein from Altana Pharma, Konstanz,
Germany) or monoclonal antibody against nitrotyrosine
(clone 1A6; dilution 1:40; Upstate, Hamburg, Germany), or
both, at 4°C overnight. The specificity of nitrotyrosine
staining was confirmed by blocking the antibody with
10 mmol/l 3-nitrotyrosine in PBS or by a reduction of
nitrotyrosine to aminotyrosine with sodium dithionite. For
visualization, the secondary antibodies (Alexa 568 anti-
rabbit immunoglobulin G [IgG] or Alexa 488 anti-mouse
IgG; dilution 1:300; Molecular Probes/MoBiTec, Go¨ttin-
gen, Germany) were incubated for 1 h at room temperature.
Sections were then rinsed, embedded in glycerin-PBS, and
examined under a fluorescent microscope (DM-IRB; Leica)
connected with a digital imaging system (Spot-RT; Diag-
nostic Instruments/Visitron Systems, Puchheim, Germany).
Negative controls were performed by eliminating the pri-
mary antibodies.
Activity assay of PGI2-S. Activity of PGI2-S was assessed
as described recently (19). Homogenates from control or
NTG-treated aortas (3 mg protein/ml) were incubated
with 100 mol/l (14C)-PGH2 for 3 min. The reaction was
stopped by acidification with 1 N HCl to pH 3.5. The
incubation media were extracted with 3 volumes of ethyl
acetate, and after centrifugation, the organic phases were
evaporated to dryness under nitrogen. Samples were then
Abbreviations and Acronyms
COX  cyclooxygenase
cGK-I  cyclic guanosine monophosphate-dependent
kinase-I
cGMP  cyclic guanosine monophosphate
LDCL  luminol-derived chemiluminescence
NO  nitric oxide
NOSIII  endothelial nitric oxide synthase
NTG  nitroglycerin
PGI2(-S)  prostacyclin (synthase)
P-VASP  phosphorylated vasodilator-stimulated
phosphoprotein
sGC  soluble guanylyl cyclase
TXA2  thromboxane A2
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resuspended in 60 l of ethyl acetate and subsequently
separated by thin-layer chromatography (ethyl acetate/
water/isooctane/acetic acid ratio 90:100:50:20). Prostanoids
were quantified as previously described (19).
Statistical analysis. Results are expressed as the mean
value  SEM. The median effective dose (ED50) value for
each experiment was obtained by logit transformation. To
compare LDCL values, PGI2-S, tyrosine-nitrated PGI2-S,
cGK-I expression, and P-VASP in vessels from sham and
NTG-treated animals, one-way analysis of variance
(ANOVA) was employed. The ED50 values (potency) for
each experiment were obtained by logarithmic transforma-
tion. Vascular responses were compared by using ANOVA
with ED50 and maximal relaxations (efficacy) as dependent
variables. The Scheffe´ post hoc test was used to examine
differences between groups when significance was indicated.
A p value 0.05 was considered statistically significant.
RESULTS
Nitroglycerin treatment, vascular production of reactive
oxygen species, and cGK-I signaling. Treatment of New
Zealand White rabbits for three days with NTG patches
significantly increased LDCL (p  0.05) (Fig. 1). To
specify the nature of reactive oxygen species detected by
LDCL, ebselen and uric acid were employed as selective
trapping agents for peroxynitrite and derived radicals. The
marked inhibitory effects in both groups indicate that
peroxynitrite contributes to LDCL with the absolute rate of
peroxynitrite formation, in particular, in vessels from NTG-
treated animals. Because increased vascular peroxynitrite
formation may indicate a reduced vascular NO content, we
used P-VASP as an indirect readout for vascular NO
bioavailability (Fig. 2), as done previously. In the setting of
tolerance, P-VASP was reduced. The addition of uric acid
or ebselen slightly but significantly enhanced the formation
of P-VASP in vessels from sham-treated animals, and this
was strikingly enhanced in tissue from NTG-treated ani-
Figure 1. Effects of nitroglycerin (NTG) treatment on luminol-derived
chemiluminescence in rabbit aortic rings. Data are expressed as the mean
value SEM. *p 0.05 vs. control (C) by analysis of variance (ANOVA).
p 0.05 vs. C and NTG by ANOVA. E ebselen; UA uric acid (100
mol/l each).
Figure 2. Effects of in vitro incubation of control (C) and tolerant aortic rings with ebselen (E) and uric acid (UA) (100 mol/l each) on the activity of
cyclic guanosine monophosphate-dependent kinase-I (cGK-I), as assessed by immunoblotting of phosphorylated vasodilator-stimulated phosphoprotein
(P-VASP). *p  0.05 vs. C by analysis of variance.
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mals, in agreement with the data presented in Figure 1.
Accordingly, in vitro incubation of tolerant tissue with
ebselen led to an improvement of the NTG dose-response
relationship (Fig. 3) (ED50—control: 7.75  0.04; control
 ebselen: 7.76  0.04; NTG: 6.97  0.06; NTG 
ebselen: 7.46  0.07; Scheffe´ post hoc test—control vs.
NTG: p  0.001; NTG vs. NTG  ebselen: p  0.0023).
Effects of NTG treatment on PGI2-S expression, ty-
rosine nitration, and activity. Activity of PGI2-S is usu-
ally already inhibited at micromolar concentrations of per-
oxynitrite. This would predict an inhibition of PGI2-S
under prolonged exposure to NTG if simultaneous forma-
tion of NO and superoxide occurred (Figs. 1 and 2). Figure
4 summarizes the effects of in vivo NTG treatment on the
expression and tyrosine nitration of PGI2-S. Treatment
with NTG did not modify the expression of PGI2-S,
whereas the amount of tyrosine-nitrated PGI2-S was
strongly increased. Using a different model of nitrate toler-
ance (NTG infusion in rats) and immunohistochemical
detection of nitrated PGI2-S, the results obtained from
rabbit aortas were confirmed (Fig. 5). In slices of aortic rings
from rats treated for three days with NTG, there was an
increased nitrotyrosine content, without altering PGI2-S
expression. The specificity of the 3-nitrotyrosine antibody in
tolerant tissue was confirmed by three control experiments.
The antibody was blocked by co-incubation with authentic
3-nitrotyrosine (5G); protein-bound 3-nitrotyrosine was
reduced by sodium dithionite before antibody incubation
(5H); and only the secondary antibody was used (5I). These
results therefore support the findings obtained with
immunoprecipitation.
The functional consequences for PGI2-S activity are
depicted in Figure 6. Treatment with NTG selectively
inhibited PGI2-S activity, as evidenced by its inhibitory
effect on the conversion of PGH2 to 6-keto-PGF1, a stable
metabolite of PGI2. A simultaneous shift of 6-keto-PGF1
to PGE2 was observed, suggesting the conversion of PGH2
to PGE2 by enzymatic or nonenzymatic pathways.
Involvement of PGI2 in NTG-induced relaxation of
control and tolerant aortas. In vitro incubation of control
tissue with U51605, the dual blocker of PGI2-S and
TXA2S, which has been previously shown to mimic the
effects of authentic peroxynitrite in organ chamber experi-
ments (19), significantly shifted NTG’s dose-response rela-
tionship to the right (Fig. 7). In contrast, it failed to modify
Figure 3. Effects of in vitro incubation of control (C) and tolerant rab-
bit aortas with ebselen (100 mol/l) on the nitroglycerin (NTG)
concentration-response relationship. Data are expressed as the mean
value  SEM.
Figure 4. (A) Western blot analysis of aortas from control and nitroglycerin (NTG)-treated rabbits. (B) The left side shows the effects of NTG treatment
on the expression of prostacyclin-synthase (PGI2-S). The right side shows the amount of tyrosine-nitrated PGI2-S present in 3-nitrotyrosine-
immunoprecipitates. Results are representative of four to six separate experiments. p  0.05 vs. control (C) by analysis of variance.
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vascular NTG responses in vessels from NTG-treated
rabbits, compatible with a substantially decreased activity of
PGI2-S. (ED50—control: 7.91  0.07; control  U51605:
7.54  0.07; NTG: 7.28  0.06; NTG  U51605: 7.37 
0.04; Scheffe´ post-hoc test—control vs. C  U51605: p 
0.0019).
DISCUSSION
The present studies demonstrate that NTG treatment
increases vascular peroxynitrite formation. Immunoprecipi-
tation experiments and immunohistochemical analysis iden-
tified PGI2-S as a nitrated protein in rabbit and rat aortas in
response to in vivo NTG treatment, leading to a marked
inhibition of PGI2-S activity. Likewise, a strong inhibition
of cGK-I activity was observed. In vitro trapping of per-
oxynitrite with ebselen and of peroxynitrite-derived radicals
with uric acid improved cGK-I activity and partially in-
creased vascular NTG sensitivity, pointing to a decisive role
of peroxynitrite in NTG-induced vascular dysfunction.
Nitroglycerin induces vasorelaxation by releasing the
vasoactive principal NO via an enzymatic biotransformation
step within mitochondria (6). The long-term use of NTG is
limited due to the rapid development of tolerance (9), which
may be at least in part due to increased production of
reactive oxygen species such as superoxide (10), favoring the
formation of the NO/superoxide reaction product peroxyni-
trite. Peroxynitrite is unstable and decomposes rapidly to
nitrite and nitrate, with a half-life of1 s at physiologic pH
(18), but during this process, it also forms hydroxyl and
nitrogen dioxide radicals. Once formed, peroxynitrite ni-
trates tyrosine residues in proteins, which can be taken as a
footprint for peroxynitrite in tissues (18). Recent studies
demonstrated that in vitro treatment of vascular tissue or in
vivo treatment of animals and patients with NTG increased
Figure 5. Immunohistochemical detection of nitrated prostacyclin-synthase (PGI2-S) in slices of aortic rings from rats with and without nitroglycerin
treatment. In tissue from sham-treated rats, nitration was virtually absent (A), PGI2-S expression was not significantly modified (B), and hence, the overlay
of both only yielded marginal background staining (C). In tolerant tissue, nitrated protein gave a clear positive signal (D), the amount of PGI2-S was
comparable to control tissue (E), and the overlay resulted in a deep yellow staining for co-localization of PGI2-S and nitration (F). The specificity of the
3-nitrotyrosine antibody in tolerant tissue was confirmed by three control experiments: 1) the antibody was blocked by co-incubation with authentic
3-nitrotyrosine (G); 2) protein-bound 3-nitrotyrosine was reduced by sodium dithionite before antibody incubation (H); and 3) only the secondary antibody
was used (I). Green fluorescence (Alexa 488-labeled secondary antibody) corresponds to nitrated protein; red fluorescence (Alexa 568-labeled secondary
antibody) to PGI2-S; and yellow to the computer-generated overlay of both stainings and, accordingly, to nitrated PGI2-S.
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the vascular and urinary nitrotyrosine content (15–17),
which can be considered as a marker of peroxynitrite-
dependent oxidative damage.
The data presented with the present studies go along with
this concept. Prolonged treatment with NTG led to about a
threefold increase in the luminol assay signal compared with
aortic segments from sham-treated controls. However,
luminol-enhanced chemiluminescence lacks specificity for
peroxynitrite, as it has been shown to increase also in
response to hydrogen peroxide, superoxide, and hydroxyl
radicals. To address this issue, we used ebselen and uric acid
(Fig. 1), which have been shown to possess a relatively
potent peroxynitrite trapping efficacy and have been recently
used to quantify vascular peroxynitrite formation in an
animal model of atherosclerosis (24). Because both com-
pounds markedly reduced the luminol signal, in particular,
in tolerant tissue (Fig. 1), it is conceivable to conclude that
a major part of the chemiluminescence signal is due to
increased vascular peroxynitrite formation.
As shown before, in vivo treatment with NTG resulted in
quite a substantial decrease in the activity of the cGK-I, as
assessed by P-VASP formation (13,14). To address the role
of peroxynitrite in inhibiting cGK-I activity, tolerant tissue
was incubated with ebselen and uric acid. Both compounds
not only corrected the NTG-induced decreases in P-VASP
but also increased P-VASP levels to 190% and 180% of
control levels, respectively (Fig. 2). Accordingly, we found
that NTG sensitivity of tolerant vessels was improved by
ebselen (Fig. 3). Based on the strong stimulatory effect of
ebselen and uric acid on the cGK-I activity of tolerant
tissue, we speculate these compounds may restore vascular
sensitivity to nitrates by inhibiting peroxynitrite-mediated
interference with endothelial nitric oxide synthase (NOSIII)
(27) and/or sGC (28).
So far, no study has addressed the consequences of
NTG-induced oxidative stress on the activity of vasodilating
Figure 6. (Left) Effects of nitroglycerin (NTG) treatment on (14C)-PGH2–dependent prostanoid production in rabbit aortas. Results are expressed as the
mean value  SEM from five experiments. *p  0.05 vs. control by analysis of variance. Solid bars  without NTG treatment; open bars  with NTG
treatment. (Right) Schematic diagram depicting the effects of NTG-induced formation of peroxynitrite (ONOO) on arachidonic acid metabolism.
ONOO inhibits the conversion of the cyclooxygenase product PGH2 (prostacyclin endoperoxide) by the prostacyclin synthase via tyrosine nitration. This
effect can be mimicked in vitro by using the prostacyclin synthase inhibitor U51605. The remaining PGH2 will act directly or indirectly (via formation of
thromboxane A2 [TXA2]) on the thromboxane receptor (TxR), leading to enhanced constriction.
Figure 7. Effects of in vitro incubation of control and tolerant aortas with
U51605 (100 mol/l) on the nitroglycerin (NTG) concentration-response
relationship. Data are expressed as the mean value  SEM.
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PGI2-S. Several groups have demonstrated that NTG or its
vasoactive metabolite NO causes relaxation, in part via
activation of cyclooxygenase-1 (COX-1) (29), leading to
enhanced formation of PGI2 in cultured endothelial cells
and vascular tissue (21,22). The presented data go along
with this concept, as the blocker of PGI2-S (i.e., U51605)
significantly shifted the NTG dose-response relationship to
higher concentrations (Fig. 7). More recent in vitro studies
have shown that PGI2-S is a preferential nitration target of
peroxynitrite (30). More importantly, these studies also
revealed that tyrosine nitration of PGI2-S resulted in an
almost complete inhibition of the activity of the enzyme
leading to decreased PGI2 formation (19,30). Because
nonmetabolized PGH2 can activate the TXA2/PGH2 re-
ceptor of vascular smooth muscle cells with negative effects
on NO-mediated vasodilation, increased vascular peroxyni-
trite concentrations can be theoretically considered as a
marker for—but also as a mediator of—endothelial dys-
function as well as “nitrate tolerance.”
To address the consequences of NTG-induced stimula-
tion of vascular peroxynitrite formation, Western blots of
3-nitrotyrosine immunoprecipitates exposed to a polyclonal
antibody directed against PGI2-S in vessels from animals
with and without NTG treatment were obtained. As de-
picted in Figure 4, we were able to detect a 52-kd protein
band demonstrating a marked increase in the nitrated
PGI2-S signal in the immunoprecipitate in tissue from
tolerant aortas compared with aortas from sham-treated
animals. This cannot be attributed to increased expression
of the enzyme, because immunoblots of vascular homoge-
nates from tolerant and nontolerant vessels showed compa-
rable signal intensity for PGI2-S. To show that this phe-
nomenon holds true for different animal models of
tolerance, immunohistochemistry studies were performed in
aortic tissue from NTG-treated rats (Fig. 5). As depicted in
Figure 5, NTG treatment increased nitration mainly in the
endothelium, subendothelial space, and adventitia. No
change was observed with respect to PGI2-S expression, and
co-localization of PGI2-S with nitrated protein was ob-
served in the endothelium and adventitia and to some extent
in the media.
As a functional consequence of tyrosine nitration of
Figure 8. Schematic diagram depicting the mechanisms underlying nitroglycerin (NTG)-induced relaxation (A) and the vascular consequences of
NTG-induced vascular peroxynitrite formation (B). (A) Short-term NTG treatment causes vasorelaxation by releasing the vasoactive metabolite nitric oxide
(NO), which, in turn, stimulates both soluble guanylyl cyclase (sGC) and release of prostacyclin (PGI2). Activation of sGC and adenylyl cyclase (AC)
increases the formation of the second messengers cyclic guanosine monophosphate (cGMP) and cAMP. Signaling pathways activated by cAMP and cGMP
may interact at different levels. Subsequent activation of cGMP- and cAMP-dependent kinase (cGK-I and cAK) will induce vasorelaxation. Activation of
cyclic guanosine monophosphate-dependent kinase-I (cGK-I) and, to some extent, cAK will cause phosphorylated vasodilator-stimulated phosphoprotein
(P-VASP) at serine 239. VASP is also phosphorylated at serine 157, which is primarily mediated by cAK and which was not analyzed in this study. (B)
Long-term treatment with NTG stimulates the production of reactive oxygen species such as peroxynitrite (ONOO). Peroxynitrite may, in turn, induce
tolerance via inhibiting the activity of the NTG-metabolizing enzyme (mitochondrial aldehyde dehydrogenase). Peroxynitrite may also cause endothelial
dysfunction via oxidization of the NOSIII co-factor tetrahydrobiopterin and by tyrosine nitration of PGI2-S associated with decreased P-VASP.
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PGI2-S, the conversion of (
14C)-PGH2 into 6-keto PGF1
was markedly inhibited in rabbit aortas (Fig. 6). We also
observed a shift toward increased PGE2 formation in
tolerant tissue. Because the expression of PGI2-S was not
affected by NTG tolerance, it is conceivable that increased
tyrosine nitration primarily accounts for the observed inhi-
bition of the activity of the enzyme in the setting of
tolerance. The functional inhibition of PGI2-S activity in
tolerant tissue was indirectly confirmed by experiments
using the dual blocker of PGI2-S and TXA2-S—U51605,
which has previously been shown to mimic the effects of
authentic peroxynitrite in organ chamber experiments (26).
Accordingly, in tolerant tissue, U51605 failed to further
shift NTG’s dose-response relationship significantly (Fig.
7), providing further evidence that the activity of this
enzyme is inhibited in response to in vivo NTG treatment.
Taken together, the presented data provide evidence that
increased peroxynitrite formation in response to long-term
NTG treatment inhibits the formation of PGI2, which may
contribute to endothelial dysfunction and an enhanced
propensity of the vasculature to vasoconstrict.
The demonstration of a crucial role for peroxynitrite in
mediating tolerance raises the question of whether the
oxidative stress concept of tolerance contradicts recent
findings by Chen et al. (6), who identified an inhibition of
the mitochondrial aldehyde dehydrogenase as the crucial
step for attenuation of vascular NTG sensitivity in response
to long-term treatment. Although this concept may hold
true for the previously observed decrease in NTG biotrans-
formation in response to “in vitro” incubation of vascular
tissue with NTG, it cannot explain why “in vivo” tolerance
is associated with endothelial dysfunction (11,12) and why
NTG treatment strongly inhibits the activity of cGK-I in
vessels from experimental animals (13) and patients (14).
The presented data may indicate that both phenomena do
not necessarily exclude each other. Nitric oxide release from
NTG mediated by the mitochondrial aldehyde dehydroge-
nase is based on a restoration of dithiol groups at the active
site of the enzyme, which is dependent on glutathione or
other free thiols (6). In the presence of increased oxidative
stress induced, for example, by continuous NTG treatment,
mitochondrial thiols will be oxidized and, as a consequence
of the lack of restoration of mitochondrial aldehyde dehy-
drogenase, the NO release by this enzyme will cease (6).
Thus, NTG-induced formation of reactive oxygen species
may explain phenomena such as endothelial dysfunction and
inhibition of cGK-I activity, but may also explain the
observed impairment of NTG biotransformation.
Clinical implications and conclusions. Tolerance has
been characterized not only by decreased sensitivity to NTG
but also by endothelial dysfunction and an increase in the
propensity of the vasculature to vasoconstrict. This scenario,
as a consequence of NTG therapy, strikingly resembles
rebound pulmonary hypertension in response to long-term
inhalation therapy with NO (31). Both models are charac-
terized by increased vasoconstrictor sensitivity, increased
oxidative stress, and increases in vascular peroxynitrite levels
(31). Recently, we have shown that oxidative stress mark-
edly increases the expression of endothelin-1 in endothelial
(32) and smooth muscle cells (33). Endothelin-1, in turn,
stimulates vascular superoxide production, which results not
only in increased endothelin-1–mediated vasoconstriction
but also in increased formation of peroxynitrite (31). The
latter, in turn, may cause tyrosine nitration of PGI2-S and
oxidation of NOSIII, leading to an inhibition of the
production of the two most important vasodilators—
antithrombotic and antiproliferative signaling pathways—in
vascular tissue. Therefore, it is conceivable that these spe-
cific side effects of NTG therapy not only contribute to
nitrate tolerance but may also be effective in other patho-
logic conditions exhibiting increased vascular peroxynitrite
formation. Inhibition of PGI2-S may also lead to an
increased release of PGH2 and activation of the TXA2/
PGH2 receptor, thereby enforcing these adverse effects.
The question may arise whether an inhibition of PGI2-S
via tyrosine nitration has some clinical relevance, particu-
larly when most patients with coronary artery disease are
already receiving treatment with the COX inhibitor aspirin
(see schematic diagrams in Figs. 6 and 8). It is important to
note that anti-inflammatory drugs inhibit COX, whereas
the enzyme PGI2-S uses the product of the COX reaction.
Aspirin, via inhibition of COX, therefore reduces the
synthesis of many prostaglandins, including PGI2 and
TXA2. Nitroglycerin-induced inhibition of PGI2-S will
come into play, particularly when low-dose aspirin, which
inhibits platelets but not vascular COX, is applied. In
contrast, impairment of PGI2-S selectively reduces the
concentrations of vasoprotective PGI2 and may (due to
increased PGH2 levels) increase TXA2 levels. Both effects
will have adverse vascular effects.
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